GLP-1 Drugs Like Ozempic May Boost Psoriasis Treatment in Patients with Obesity
New NPF primer finds GLP-1 receptor agonists improve psoriasis outcomes and quality of life when added to standard treatments in obese patients.
Summary
A National Psoriasis Foundation primer published in JAMA Dermatology concludes that GLP-1 receptor agonists — drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound) — may meaningfully improve psoriasis outcomes when added to standard treatments, especially in patients with obesity. Multiple studies show these drugs reduce psoriasis severity scores, lower inflammatory markers like C-reactive protein and interleukin-6, and improve quality of life. Weight loss driven by GLP-1s appears to enhance how well existing psoriasis medications work. Early trial data from the TOGETHER-PsA study also show tirzepatide combined with ixekizumab outperforms the biologic alone. Experts say dermatologists should consider prescribing these agents as an adjunct for select patients with metabolic comorbidities.
Detailed Summary
A newly published primer from the National Psoriasis Foundation, appearing in JAMA Dermatology, makes the case that GLP-1 receptor agonists deserve serious consideration as add-on therapy for psoriasis patients — particularly those living with obesity. This matters for longevity-minded readers because psoriasis is a chronic inflammatory disease linked to elevated cardiovascular risk, metabolic dysfunction, and reduced healthspan, and GLP-1 drugs address several of these overlapping pathways simultaneously.
The primer reviewed mounting evidence showing that GLP-1 agonists such as semaglutide and liraglutide, as well as dual GIP/GLP-1 agents like tirzepatide, produce clinically meaningful reductions in the Psoriasis Area and Severity Index (PASI). Beyond skin improvement, these drugs were associated with lower levels of C-reactive protein, interleukin-6, lipids, and visceral adiposity — all key inflammatory and metabolic biomarkers relevant to aging and disease risk.
Small translational studies found correlations between PASI score improvements and reductions in superficial adiposity and dermal immune cell density, suggesting a genuine biological mechanism rather than coincidental benefit. Importantly, GLP-1 agents appear safe to combine with standard psoriasis treatments including methotrexate, cyclosporine, and biologics.
Early clinical trial data are beginning to confirm these findings. The TOGETHER-PsA trial reported that adding tirzepatide to the biologic ixekizumab significantly increased the proportion of psoriatic arthritis patients achieving dual endpoints of disease improvement and weight loss compared to the biologic alone. A companion trial in plaque psoriasis is ongoing and showing promising early signals.
However, much of the existing evidence comes from small, short-duration studies without control groups. Experts stress that larger randomized controlled trials are needed before definitive recommendations can be made. For now, the primer positions GLP-1s as a biologically plausible and clinically intriguing adjunct for carefully selected patients with psoriasis and metabolic comorbidities.
Key Findings
- GLP-1 drugs reduced psoriasis severity scores and improved quality of life across multiple studies in obese patients.
- Semaglutide and liraglutide lowered CRP, IL-6, lipids, and visceral fat — key inflammatory and metabolic biomarkers.
- GLP-1 agents are safe to combine with methotrexate, cyclosporine, and biologic psoriasis therapies.
- TOGETHER-PsA trial: tirzepatide plus ixekizumab outperformed ixekizumab alone on dual disease and weight endpoints.
- Weight loss from GLP-1s appears to directly enhance the effectiveness of existing psoriasis medications.
Methodology
This is a news report summarizing a clinical primer published in JAMA Dermatology, a peer-reviewed journal, authored by dermatology experts including NPF-affiliated researchers. The evidence base includes multiple observational studies, small translational studies, and early randomized trial data from the TOGETHER-PsA trial; most underlying studies are small and lack control groups.
Study Limitations
Much of the supporting evidence comes from small, short-duration, uncontrolled studies, limiting definitive conclusions. Larger randomized controlled trials such as TOGETHER-PsO are still ongoing. Readers should consult primary sources in JAMA Dermatology and await full trial results before drawing firm clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.